Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Octopuses have two sexes and have only one gonad (testis in males and ovary in females) located posteriorly. The gonad deposits gametes into an adjacent cavity called the gonocoel. A gonoduct bridges the gonocoel with the mantle cavity. An optic gland creates hormones that cause the octopus to mature and age and stimulate gamete production. The timing of reproduction and lifespan depends on environmental conditions such as temperature, light and nutrition, which trigger the gland. The male has a specialised arm called a hectocotylus which it uses to transfer spermatophores (packets of sperm) into the female's mantle cavity. The hectocotylus in Octopus is usually the R3 arm, which has a spoon-shaped depression and a suckerless tip. Fertilisation may occur in the mantle cavity or in the surrounding water. Reproduction has been studied in some species. In the giant Pacific octopus, courtship includes changes in skin texture and colour, mostly in the male. The male may cling to the top or side of the female or position himself beside her. There is some speculation that he may first use his hectocotylus to remove any spermatophore or sperm already present in the female. He picks up a spermatophore from his spermatophoric sac with the hectocotylus, inserts it into the female's mantle cavity, and deposits it in the correct location in the opening of the oviduct. Two spermatophores are transferred in this way; these are about one metre (yard) long, and the empty ends may protrude from the female's mantle. A complex hydraulic mechanism releases the sperm from the spermatophore.
== Structure and function == PPO is listed as a morpheein, a protein that can form two or more different homo-oligomers (morpheein forms), but must come apart and change shape to convert between forms. It exists as a monomer, trimer, tetramer, octamer or dodecamer, creating multiple functions. In plants, PPO is a plastidic enzyme with unclear synthesis and function. In functional chloroplasts, it may be involved in oxygen chemistry like mediation of pseudocyclic photophosphorylation. Enzyme nomenclature differentiates between monophenol oxidase enzymes (tyrosinases) and o-diphenol:oxygen oxidoreductase enzymes (catechol oxidases). The substrate preference of tyrosinases and catechol oxidases is controlled by the amino acids around the two copper ions in the active site.
=== Other properties === Another important property for potential applications is the extent of phase separation, represented by the difference in polymer content in the two phases after phase separation. For most applications, phase separation in pure polymer and pure solvent would be desirable although it is practically impossible. The extent of phase separation in a given temperature interval depends on the particular polymer-solvent phase diagram. Example: From the phase diagram of polystyrene (molar mass 43,600 g/mol) in the solvent cyclohexane it follows that at a total polymer concentration of 10%, cooling from 25 to 20 °C causes phase separation into a polymer-poor phase with 1% polymer and a polymer-rich phase with 30% polymer content. Also desirable for many applications is a sharp phase transition, which is reflected by a sudden drop in transmittance. The sharpness of the phase transition is related to the extent of phase separation but additionally relies on whether all present polymer chains exhibit the same cloud point. This depends on the polymer endgroups, dispersity, or—in the case of copolymers—varying copolymer compositions. As a result of phase separation, thermoresponsive polymer systems can form well-defined self-assembled nanostructures with a number of different practical application such as in drug and gene delivery, tissue engineering, etc.
A cumulative constant can always be expressed as the product of stepwise constants. Conversely, any stepwise constant can be expressed as a quotient of two or more overall constants. There is no agreed notation for stepwise constants, though a symbol such as KLML is sometimes found in the literature. It is good practice to specify each stability constant explicitly, as illustrated above.
Sources: en.wikipedia.org
An opioid antagonist, or opioid receptor antagonist, is a receptor antagonist that acts on one or more of the opioid receptors. Opioid antagonists can work on receptors in the peripheral nervous system or central nervous system. They are different from opioid agonists, although they also bind to opioid receptors, often with more affinity than agonists, they either do not activate the receptor, or activate it less than endorphins.
== Sources == This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The State of Food and Agriculture 2019. Moving forward on food loss and waste reduction, In brief, 24, FAO, FAO.
Sex reassignment operations (gender-affirming surgery) have been performed in Thailand since 1975, and Thailand is among the most popular destinations globally for patients seeking such operations. Puberty blockers and cross sex hormones are also available to minors in Thailand. Transgender people are quite common in Thai popular entertainment, television shows and nightclub performances, however, transgender people lack various legal rights compared to the rest of the population, and may face discrimination from society. Transgender women, known as kathoeys, have access to hormones through non-prescription sources. This kind of access is a result of the low availability and expense of transgender health care clinics. However, transgender men have difficulty gaining access to hormones such as testosterone in Thailand because it is not as readily available as hormones for kathoeys. As a result, just a third of all trans men surveyed are taking hormones to transition whereas almost three quarters of kathoeys surveyed are taking hormones.
Sources: en.wikipedia.org
== Medical uses == Approved indication for dihydrocodeine is the management of moderate to moderately severe pain as well as coughing and shortness of breath. As is the case with other drugs in this group, the antitussive dose tends to be less than the analgesic dose, and dihydrocodeine is a powerful cough suppressant like all other members of the immediate codeine family (see below) and their cousins hydrocodone, oxycodone and ethylmorphine, whole opium preparations, and the strong opioid hydromorphone. For use against pain, dihydrocodeine is usually formulated as tablets or capsules containing 15–16 mg or 30–32 mg with or without other active ingredients such as aspirin, paracetamol (acetaminophen), ibuprofen, or others. Controlled release dihydrocodeine is available for both pain and coughing, as indicated below, as waxy tablets containing 60 to 120 mg of the drug. Some formulations, intended for use against coughing and the like, have other active ingredients such as antihistamines, decongestants and others. Other oral formulations, such as packets of effervescent powder, sublingual drops, elixirs and the like are also available in many locations. Injectable dihydrocodeine is most often given as a deep subcutaneous injection. Dihydrocodeine appears to be superior to tramadol in treating pain.
== Mechanism of action == Nalfurafine is an orally active, centrally acting, highly potent, selective full agonist of the κ-opioid receptor (KOR) (Ki = 75 pM; EC50 = 25 pM). As touched on above, nalfurafine shows atypical properties as a KOR agonist relative to other drugs. Notably, it does not completely substitute for the prototypical KOR agonist U-50488 in rodents, indicating qualitative differences in the discriminative effects of the two compounds. Moreover, unlike U-50488, it produces neither conditioned place aversion or preference in rodents. The drug is a 4,5-epoxymorphinan derivative, and is structurally unique relative to other KOR agonists. Nalfurafine may be a biased agonist of the KOR or a KOR subtype-selective agonist. Indeed, it has been found to act as a biased agonist of the KOR, preferring activation of β-arrestin signaling in vitro, but paradoxically, β-arrestin appears to be responsible for KOR agonist-induced aversion, and nalfurafine furthermore shows paradoxical effects in vivo that are not consistent with its in vitro profile. As such, more research is needed to clarify the distinct mechanisms and effects of this drug. Nalfurafine has been found in vitro to bind to the μ-opioid receptor and to possess weak partial agonist activity at this site, albeit with much lower affinity relative to the KOR. However, in vivo, nalfurafine has shown no indications of MOR agonism or antagonism in animals or humans, including no evidence of rewarding or reinforcing effects or physical dependence.
== Pharmacokinetics == Tofisopam is also claimed to be a PDE10A inhibitor, which may provide an alternative mechanism of action for its various therapeutic effects, and this action has been proposed to make tofisopam potentially useful as a treatment for schizophrenia. Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and some researches suspect that this could cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.
For example, metro stations in Pyongyang, North Korea, were constructed 110 metres (360 ft) below ground, and were designed to serve as nuclear shelters in the event of war, with each station entrance built with thick steel blast doors. An example of privately funded fallout shelters is the Ark Two Shelter in Ontario, Canada, and autonomous shelters have been constructed with an emphasis on post-war networking and reconstruction. In Switzerland, the majority of homes have an underground blast and fallout shelter. The country has an overcapacity of such shelters and can accommodate slightly more than the nation's population size. While the nuclear fallout shelters described above are the ideal long-term protection methods against dangerous radiation exposure in the event of a nuclear catastrophe, it is also necessary to have mobile protection equipment for medical and security personnel to safely assist in containment, evacuation, and many other necessary public safety objectives which ensue as a result of nuclear detonation. There are many basic shielding strategies used to protect against the deposition of radioactive material from external radiation environments. Respirators that protect against internal deposition are used to prevent the inhalation and ingestion of radioactive material and dermal protective equipment which is used to protect against the deposition of material on external structures like skin, hair, and clothing.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.